NFKB1 and COVID-19: Since the “TNF-α signaling via NF-κB” pathway was the main enhanced pathway during PD and was the significantly enriched pathway for eight brain regions, it seems that inhibition of this pathway can be an appropriate approach to counteract the neurotoxic effect of αSN and also reduce the severe effects of COVID-19 on PD patients.